Literature DB >> 17597457

Ribavirin up-regulates the activity of double-stranded RNA-activated protein kinase and enhances the action of interferon-alpha against hepatitis C virus.

Wei-Liang Liu1, Wen-Cheng Su, Ching-Wei Cheng, Lih-Hwa Hwang, Chih-Chiang Wang, Hui-Ling Chen, Ding-Shinn Chen, Ming-Yang Lai.   

Abstract

BACKGROUND: Ribavirin's mechanism of action in the treatment of chronic hepatitis C remains to be clarified. Double-stranded RNA-activated protein kinase (PKR) plays a role in cell defense against virus infection. This study investigated whether PKR is a mediator of the effectiveness of ribavirin, used either alone or in combination with interferon (IFN)- alpha , against hepatitis C virus (HCV) infection.
METHODS: Primary human hepatocytes and HCV-replicon cells were treated with ribavirin and/or IFN- alpha . PKR activity was assayed by immunoblotting. A pulse-chase assay of the half-life of PKR protein was performed to study whether ribavirin decreases PKR degradation. We used small-interference RNA (siRNA) to knock down PKR to assess its importance in the suppression of HCV-RNA replication in the replicon system.
RESULTS: Ribavirin was able to up-regulate the levels of phosphorylated PKR and phosphorylated eIF2 alpha , leading to suppression of HCV-RNA replication. The effects that treatment with ribavirin plus IFN- alpha had on PKR activity were greater than those observed for treatment with either ribavirin alone or IFN- alpha alone. Knockdown of PKR increased HCV-RNA replication, supporting the importance of PKR in the control of HCV-RNA replication. The pulse-chase experiment showed that ribavirin can reduce the degradation rate of PKR protein.
CONCLUSION: These results suggest that the anti-HCV action of ribavirin is partly attributable to its ability to up-regulate PKR activity.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17597457     DOI: 10.1086/518894

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  14 in total

Review 1.  The application and mechanism of action of ribavirin in therapy of hepatitis C.

Authors:  Emmanuel Thomas; Marc G Ghany; T Jake Liang
Journal:  Antivir Chem Chemother       Date:  2012-09-25

2.  Activation of the Ras/Raf/MEK pathway facilitates hepatitis C virus replication via attenuation of the interferon-JAK-STAT pathway.

Authors:  Qi Zhang; Rui Gong; Jing Qu; Yijing Zhou; Weiyong Liu; Mingzhou Chen; Yingle Liu; Ying Zhu; Jianguo Wu
Journal:  J Virol       Date:  2011-11-23       Impact factor: 5.103

3.  Pegylated IFN-α suppresses hepatitis C virus by promoting the DAPK-mTOR pathway.

Authors:  Wei-Liang Liu; Hung-Chih Yang; Ching-Sheng Hsu; Chih-Chiang Wang; Tzu-San Wang; Jia-Horng Kao; Ding-Shinn Chen
Journal:  Proc Natl Acad Sci U S A       Date:  2016-12-06       Impact factor: 11.205

4.  Ribavirin improves early responses to peginterferon through improved interferon signaling.

Authors:  Jordan J Feld; Glen A Lutchman; Theo Heller; Koji Hara; Julie K Pfeiffer; Richard D Leff; Claudia Meek; Maria Rivera; Myung Ko; Christopher Koh; Yaron Rotman; Marc G Ghany; Vanessa Haynes-Williams; Avidan U Neumann; T Jake Liang; Jay H Hoofnagle
Journal:  Gastroenterology       Date:  2010-03-17       Impact factor: 22.682

5.  Evolution of interferon-based therapy for chronic hepatitis C.

Authors:  Chun-Hao Chen; Ming-Lung Yu
Journal:  Hepat Res Treat       Date:  2010-10-10

6.  Interferon-alpha-induced mTOR activation is an anti-hepatitis C virus signal via the phosphatidylinositol 3-kinase-Akt-independent pathway.

Authors:  Azusa Matsumoto; Tatsuki Ichikawa; Kazuhiko Nakao; Hisamitsu Miyaaki; Kumi Hirano; Masumi Fujimito; Motohisa Akiyama; Satoshi Miuma; Eisuke Ozawa; Hidetaka Shibata; Shigeyuki Takeshita; Hironori Yamasaki; Masanori Ikeda; Nobuyuki Kato; Katsumi Eguchi
Journal:  J Gastroenterol       Date:  2009-05-13       Impact factor: 7.527

7.  Ribavirin improves the IFN-γ response of natural killer cells to IFN-based therapy of hepatitis C virus infection.

Authors:  Jens M Werner; Elisavet Serti; Xenia Chepa-Lotrea; Jonathan Stoltzfus; Golo Ahlenstiel; Mazen Noureddin; Jordan J Feld; T Jake Liang; Yaron Rotman; Barbara Rehermann
Journal:  Hepatology       Date:  2014-08-13       Impact factor: 17.425

Review 8.  Interferon at the cellular, individual, and population level in hepatitis C virus infection: Its role in the interferon-free treatment era.

Authors:  Rubesh Raja; Subhasish Baral; Narendra M Dixit
Journal:  Immunol Rev       Date:  2018-09       Impact factor: 12.988

9.  Ribavirin enhances IFN-α signalling and MxA expression: a novel immune modulation mechanism during treatment of HCV.

Authors:  Nigel J Stevenson; Alison G Murphy; Nollaig M Bourke; Catherine A Keogh; John E Hegarty; Cliona O'Farrelly
Journal:  PLoS One       Date:  2011-11-16       Impact factor: 3.240

10.  Ribavirin enhances the action of interferon-α against hepatitis C virus by promoting the p53 activity through the ERK1/2 pathway.

Authors:  Wei-Liang Liu; Hung-Chih Yang; Wen-Cheng Su; Chih-Chiang Wang; Hui-Ling Chen; Hurng-Yi Wang; Wen-Hung Huang; Ding-Shinn Chen; Ming-Yang Lai
Journal:  PLoS One       Date:  2012-09-04       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.